World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
41119
World Ranking
15860
National Ranking
7981

Monica M. Bertagnolli publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Monica M. Bertagnolli sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 284 publications — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Monica M. Bertagnolli D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Monica M. Bertagnolli sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Monica M. Bertagnolli is affiliated with Brigham and Women's Hospital in the United States. Their research primarily focuses on medicine, with a significant emphasis on oncology. The subfields of study include oncology, public health, environmental and occupational health, economics and econometrics, cancer research, and pathology and forensic medicine.

The main topics of their work cover colorectal cancer treatments and studies, genetic factors in colorectal cancer, cancer genomics and diagnostics, as well as health systems, economic evaluations, and quality of life. Additional topics include the economic and financial impacts of cancer, health and medical research impacts, and ethics in clinical research.

Frequent publication venues for their work include:

  • UNC Libraries
  • Journal of Clinical Oncology
  • Clinical Trials
  • JAMA
  • Clinical Cancer Research

Frequent co-authors in their publications are:

  • Federico Innocenti (18 joint publications)
  • Alan P. Venook (17 joint publications)
  • Richard M. Goldberg (14 joint publications)
  • Donna Niedzwiecki (13 joint publications)
  • Jeffrey A. Meyerhardt (12 joint publications)

Selected recent papers include:

  • Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), 2020, Clinical Trials
  • Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology, 2020, Journal of Clinical Oncology
  • Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer, 2021, JAMA
  • Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance), 2021, Annals of Oncology
  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial, 2020, UNC Libraries

Best Publications

  • Comprehensive molecular characterization of human colon and rectal cancer

    Donna M. Muzny;Matthew N. Bainbridge;Kyle Chang;Huyen H. Dinh

  • Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

    Itay Tirosh;Benjamin Izar;Benjamin Izar;Sanjay M. Prakadan;Marc H. Wadsworth

  • Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

    Scott D. Solomon;John J.V. McMurray;Marc A. Pfeffer;Janet Wittes

  • Molecular Basis of Colorectal Cancer

    Sanford D. Markowitz;Monica M. Bertagnolli

  • Celecoxib for the Prevention of Sporadic Colorectal Adenomas

    Monica M. Bertagnolli;Craig J. Eagle;Ann G. Zauber;Mark Redston

  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

    Alan P. Venook;Donna Niedzwiecki;Heinz Josef Lenz;Federico Innocenti

  • Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

    Michael C. Heinrich;Kouros Owzar;Christopher L. Corless;Donna Hollis

  • Cyclooxygenase-2 Overexpression and Tumor Formation Are Blocked by Sulindac in a Murine Model of Familial Adenomatous Polyposis

    Susan K. Boolbol;Andrew J. Dannenberg;Amy Chadburn;Charles Martucci

  • Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors

    Chandrajit P. Raut;Matthew Posner;Jayesh Desai;Jeffrey A. Morgan

  • Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia

    Joyce A. O’Shaughnessy;Gary J. Kelloff;Gary B. Gordon;Andrew J. Dannenberg

  • CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

    Alan P. Venook;Donna Niedzwiecki;Heinz-Josef Lenz;Federico Innocenti

  • Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

    Monica M. Bertagnolli;Donna Niedzwiecki;Carolyn C. Compton;Hejin P. Hahn

  • Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis

    Najjia N. Mahmoud;Adelaide M. Carothers;Dezider Grunberger;Robyn T. Bilinski

  • Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis

    Scott D. Solomon;Janet Wittes;Peter V. Finn;Robert Fowler

  • Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers

    Ajay Goel;Christian N. Arnold;Christian N. Arnold;Donna Niedzwiecki;John M. Carethers;John M. Carethers

  • Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

    Scott D. Solomon;Marc A. Pfeffer;John J.V. McMurray;Rob Fowler

  • Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

    Alan P. Venook;Donna Niedzwiecki;Federico Innocenti;Briant Fruth

  • The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer

    Ajay Goel;Takeshi Nagasaka;Christian N. Arnold;Toru Inoue

  • Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803

    Shuji Ogino;Kaori Shima;Jeffrey A. Meyerhardt;Nadine J. McCleary

  • Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

    I. Tirosh;B. Izar;D. Treacy;J. J. Trombetta

Frequent Co-Authors

Donna Niedzwiecki
Donna Niedzwiecki Duke University
Robert J. Mayer
Robert J. Mayer Dana-Farber Cancer Institute
Alan P. Venook
Alan P. Venook University of California, San Francisco
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Chandrajit P. Raut
Chandrajit P. Raut Brigham and Women's Hospital
Ann G. Zauber
Ann G. Zauber Memorial Sloan Kettering Cancer Center
Federico Innocenti
Federico Innocenti University of North Carolina at Chapel Hill
Charles D. Blanke
Charles D. Blanke Oregon Health & Science University
Mark Redston
Mark Redston Brigham and Women's Hospital
C. Richard Boland
C. Richard Boland University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online nursing and healthcare degrees can expand your professional opportunities in medicine. Many students seek flexible options, such as rn to bsn programs without clinicals, which allow registered nurses to advance their qualifications without the traditional classroom and clinical requirements.

For those holding a master’s degree in nursing, the shortest post master's dnp program can help accelerate your journey to the highest level of clinical practice. If you are searching for time-efficient and less demanding ways to earn your Doctor of Nursing Practice, you can review community feedback on programs touted as the easiest dnp program reddit recommends.

Alternatively, aspiring nurses might consider entry-level pathways such as lpn online programs, which provide fast-track options to become a licensed practical nurse. Each of these online degrees offers distinct benefits, making medical education more accessible to those with diverse backgrounds and goals.

Best Scientists Citing Monica M. Bertagnolli

Trending Scientists

Recently Published Articles